系统性硬化症相关间质性肺病的全国性队列影响追踪
该研究基于挪威全国系统性硬化症队列(815例,2000-2012年),前瞻性评估间质性肺病(ILD)的影响。基线时50%患者(324例)存在ILD,46%出现符合ILD进展的肺功能下降;死亡率与肺纤维化范围相关,无纤维化者SMR为2.2,纤维化>25%者SMR为8.0。基线FVC正常(80-100%)者中,有纤维化者5年和10年生存率分别为69%和56%,无纤维化者为83%和80%(P=0.03)。结论提示所有SSc患者应进行基线肺功能和HRCT筛查以早期诊断ILD。
要点
- 基线50%的SSc患者存在ILD,46%出现符合ILD进展的肺功能下降。
- 死亡率随肺纤维化范围增加,SMR从无纤维化2.2升至>25%纤维化的8.0。
- 基线FVC正常者中,肺纤维化存在与否仍显著影响5年和10年生存率。
核心结论
- 基线时ILD的存在即影响SSc患者结局,建议所有SSc患者进行基线肺功能和HRCT筛查以早期诊断ILD并指导管理。
研究设计与样本
- 前瞻性评估挪威全国系统性硬化症队列(Nor-SSc),纳入2000至2012年全国所有815例SSc患者。
- 基线HRCT可用于纤维化定量者650例(80%),基线肺功能检测者703例(86%),随访重复评估。
- 研究终点(2018年)在630例新发Nor-SSc病例和15例个体匹配对照中估算生存状态和标准化死亡比(SMR)。
主要发现
- 基线时50%的SSc患者(324例)经HRCT诊断ILD,46%显示符合ILD进展的肺功能下降。
- 死亡率与肺纤维化范围相关,SMR从无纤维化的2.2增至纤维化>25%的8.0。
- SMR与基线FVC%呈负相关,在FVC低于100%的所有水平均升高。
- 基线FVC正常范围(80-100%)者中,无纤维化者5年和10年生存率分别为83%和80%,有纤维化者为69%和56%(P=0.03)。
临床怎么用
- 所有SSc患者应接受基线肺功能检测和肺部HRCT筛查以早期诊断ILD。
- 根据肺纤维化范围和基线FVC%评估死亡风险,指导进一步管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Interstitial lung disease (ILD) represents a major challenge in systemic sclerosis (SSc), but there are no precise, population-based data on its overall impact, limiting opportunities for screening and management strategies.Objectives: Evaluate impact of ILD in a unique, nationwide, population-based SSc cohort.Methods: ILD was assessed prospectively in the Norwegian SSc (Nor-SSc) cohort, including all 815 patients with SSc resident in the country from 2000 to 2012. Lung high-resolution computed tomography (HRCT) scans were available for fibrosis quantification at baseline (n = 650, 80%) and follow-up. Pulmonary function tests were assessed at baseline (n = 703, 86%) and follow-up. Vital status and standardized mortality ratios (SMRs) were estimated at study end (2018) in the 630 incident Nor-SSc cases and 15 individually matched control subjects. Cumulative survival rates were computed.Measurements and Main Results: At baseline, 50% of the subjects with SSc (n = 324) had ILD by HRCT and 46% displayed pulmonary function declines consistent with ILD progression. Mortality correlated with extent of lung fibrosis as SMR increased from 2.2 with no fibrosis to 8.0 with greater than 25% fibrosis. SMR was inversely related to baseline FVC% and increased at all FVC levels below 100%. In patients with normal-range baseline FVC (80-100%), the 5- and 10-year survival rates correlated with presence or absence of lung fibrosis, being 83% and 80%, respectively, with no fibrosis and 69% and 56%, respectively, with lung fibrosis (P = 0.03).Conclusions: The mere presence of ILD at baseline appears to affect outcome in SSc, suggesting that all patients with SSc should undergo a baseline pulmonary function test and lung HRCT screening to diagnose ILD early and tailor further management.
引用
- Hoffmann-Vold AM, Fretheim H, Halse AK, et al. Tracking Impact of Interstitial Lung Disease in Systemic Sclerosis in a Complete Nationwide Cohort. Am J Respir Crit Care Med. 2019. PMID: 31310156. doi:10.1164/rccm.201903-0486OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。